These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37922438)

  • 1. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of
    Tagawa ST; Thomas C; Sartor AO; Sun M; Stangl-Kremser J; Bissassar M; Vallabhajosula S; Huicochea Castellanos S; Nauseef JT; Sternberg CN; Molina A; Ballman K; Nanus DM; Osborne JR; Bander NH
    J Clin Oncol; 2024 Mar; 42(7):842-851. PubMed ID: 37922438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Tagawa ST; Vallabhajosula S; Christos PJ; Jhanwar YS; Batra JS; Lam L; Osborne J; Beltran H; Molina AM; Goldsmith SJ; Bander NH; Nanus DM
    Cancer; 2019 Aug; 125(15):2561-2569. PubMed ID: 31012963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
    Tagawa ST; Milowsky MI; Morris M; Vallabhajosula S; Christos P; Akhtar NH; Osborne J; Goldsmith SJ; Larson S; Taskar NP; Scher HI; Bander NH; Nanus DM
    Clin Cancer Res; 2013 Sep; 19(18):5182-91. PubMed ID: 23714732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
    Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the tolerability and safety of [
    Ling SW; van der Veldt AAM; Konijnenberg M; Segbers M; Hooijman E; Bruchertseifer F; Morgenstern A; de Blois E; Brabander T
    BMC Cancer; 2024 Jan; 24(1):146. PubMed ID: 38287346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival outcomes of salvage [
    Ballal S; Yadav MP; Satapathy S; Raju S; Tripathi M; Damle NA; Sahoo RK; Bal C
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3777-3789. PubMed ID: 37462775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mCRPC Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Mdlophane A; Maes A; Mokoala K; Mathabe K; Van C; Wiele D; Morgenstern A
    J Nucl Med; 2022 Oct; 63(10):1496-1502. PubMed ID: 35177427
    [No Abstract]   [Full Text] [Related]  

  • 9. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
    Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
    Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (
    Niaz MJ; Batra JS; Walsh RD; Ramirez-Fort MK; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
    Oncologist; 2020 Jun; 25(6):477-e895. PubMed ID: 31999003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
    Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Bander NH
    J Clin Oncol; 2004 Jul; 22(13):2522-31. PubMed ID: 15173215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
    Autio KA; Higano CS; Nordquist L; Appleman LJ; Zhang T; Zhu XH; Babiker H; Vogelzang NJ; Prasad SM; Schweizer MT; Madan RA; Billotte S; Cavazos N; Bogg O; Li R; Chan K; Cho H; Kaneda M; Wang IM; Zheng J; Tang SY; Hollingsworth R; Kern KA; Petrylak DP
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
    Petrylak DP; Vogelzang NJ; Chatta K; Fleming MT; Smith DC; Appleman LJ; Hussain A; Modiano M; Singh P; Tagawa ST; Gore I; McClay EF; Mega AE; Sartor AO; Somer B; Wadlow R; Shore ND; Olson WC; Stambler N; DiPippo VA; Israel RJ
    Prostate; 2020 Jan; 80(1):99-108. PubMed ID: 31742767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
    Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Clinical Results for PSMA-Targeted α-Therapy Using
    Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
    J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
    Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
    Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.